Larimar Therapeutics Inc has a consensus price target of $19.5 based on the ratings of 5 analysts. The high is $25 issued by JMP Securities on May 31, 2024. The low is $14 issued by Citigroup on May 22, 2024. The 3 most-recent analyst ratings were released by JMP Securities, Citigroup, and JMP Securities on May 31, 2024, May 22, 2024, and May 21, 2024, respectively. With an average price target of $21.33 between JMP Securities, Citigroup, and JMP Securities, there's an implied 124.56% upside for Larimar Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/31/2024 | Buy Now | 163.16% | JMP Securities | Jonathan Wolleben | $25 → $25 | Reiterates | Market Outperform → Market Outperform | Get Alert |
05/22/2024 | Buy Now | 47.37% | Citigroup | Samantha Semenkow | $10 → $14 | Maintains | Buy | Get Alert |
05/21/2024 | Buy Now | 163.16% | JMP Securities | Jonathan Wolleben | → $25 | Reiterates | Market Outperform → Market Outperform | Get Alert |
04/03/2024 | Buy Now | 163.16% | Leerink Partners | Joori Park | → $25 | Initiates | → Outperform | Get Alert |
03/15/2024 | Buy Now | 163.16% | JMP Securities | Jonathan Wolleben | → $25 | Reiterates | Market Outperform → Market Outperform | Get Alert |
03/12/2024 | Buy Now | 163.16% | JMP Securities | Jonathan Wolleben | → $25 | Reiterates | Market Outperform → Market Outperform | Get Alert |
02/13/2024 | Buy Now | 5.26% | Citigroup | Samantha Semenkow | $4.5 → $10 | Maintains | Buy | Get Alert |
02/13/2024 | Buy Now | 163.16% | JMP Securities | Jonathan Wolleben | $17 → $25 | Maintains | Market Outperform | Get Alert |
11/17/2023 | Buy Now | -52.63% | Citigroup | Samantha Semenkow | → $4.5 | Upgrade | Neutral → Buy | Get Alert |
08/15/2023 | Buy Now | 78.95% | JMP Securities | Jonathan Wolleben | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
05/18/2023 | Buy Now | -52.63% | Citigroup | Samantha Semenkow | $7 → $4.5 | Maintains | Neutral | Get Alert |
05/17/2023 | Buy Now | 47.37% | Guggenheim | Yatin Suneja | $12 → $14 | Maintains | Buy | Get Alert |
05/16/2023 | Buy Now | 57.89% | JMP Securities | Jonathan Wolleben | → $15 | Reiterates | Market Outperform → Market Outperform | Get Alert |
05/15/2023 | Buy Now | -26.32% | Citigroup | Samantha Semenkow | → $7 | Maintains | Neutral | Get Alert |
03/15/2023 | Buy Now | 26.32% | Guggenheim | Yatin Suneja | → $12 | Reiterates | → Buy | Get Alert |
03/14/2023 | Buy Now | 57.89% | JMP Securities | Jonathan Wolleben | $15 → $15 | Maintains | Market Outperform | Get Alert |
03/01/2023 | Buy Now | 57.89% | JMP Securities | Jonathan Wolleben | → $15 | Maintains | Market Outperform | Get Alert |
01/24/2023 | Buy Now | 68.42% | JMP Securities | Jonathan Wolleben | $16 → $16 | Maintains | Market Outperform | Get Alert |
12/13/2022 | Buy Now | -57.89% | Citigroup | Samantha Semenkow | → $4 | Initiates | → Neutral | Get Alert |
10/19/2022 | Buy Now | 26.32% | Guggenheim | Yatin Suneja | → $12 | Initiates | → Buy | Get Alert |
09/19/2022 | Buy Now | 68.42% | JMP Securities | Jonathan Wolleben | $10 → $16 | Maintains | Market Outperform | Get Alert |
09/19/2022 | Buy Now | — | William Blair | Myles Minter | — | Upgrade | Market Perform → Outperform | Get Alert |
02/15/2022 | Buy Now | — | William Blair | Myles Minter | — | Downgrade | Outperform → Market Perform | Get Alert |
The latest price target for Larimar Therapeutics (NASDAQ:LRMR) was reported by JMP Securities on May 31, 2024. The analyst firm set a price target for $25.00 expecting LRMR to rise to within 12 months (a possible 163.16% upside). 10 analyst firms have reported ratings in the last year.
The latest analyst rating for Larimar Therapeutics (NASDAQ:LRMR) was provided by JMP Securities, and Larimar Therapeutics reiterated their market outperform rating.
The last upgrade for Larimar Therapeutics Inc happened on November 17, 2023 when Citigroup raised their price target to $4.5. Citigroup previously had a neutral for Larimar Therapeutics Inc.
The last downgrade for Larimar Therapeutics Inc happened on February 15, 2022 when William Blair changed their price target from N/A to N/A for Larimar Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Larimar Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Larimar Therapeutics was filed on May 31, 2024 so you should expect the next rating to be made available sometime around May 31, 2025.
While ratings are subjective and will change, the latest Larimar Therapeutics (LRMR) rating was a reiterated with a price target of $25.00 to $25.00. The current price Larimar Therapeutics (LRMR) is trading at is $9.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.